Reaktionsgleichung
Br[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([O:16][C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1.[S:24]1(=[O:30])(=[O:29])[CH2:28][CH2:27][CH2:26][NH:25]1>>[O:29]=[S:24]1(=[O:30])[CH2:28][CH2:27][CH2:26][N:25]1[C:2]1[N:7]=[CH:6][C:5]([C:8]([N:10]2[CH2:15][CH2:14][CH:13]([O:16][C:17]3[CH:22]=[CH:21][C:20]([CH3:23])=[CH:19][CH:18]=3)[CH2:12][CH2:11]2)=[O:9])=[CH:4][CH:3]=1Komponenten
3
Versuchsvorschrift
Using (6-bromopyridin-3-yl)[4-(p-tolyloxy)piperidin-1-yl]methanone (548 mg) described in Preparation Example 193 and isothiazolidine 1,1-dioxide (177 mg) and by the reaction and treatment in the same manner as in Example 1, the title compound (146 mg) was obtained.
Quellen und Nachweise
- ORD-Eintrag
- ord-f66682ffb894410facd9ebf5d49a349b
- Quelldatensatz
- uspto-grants-2014_08
- Patentnummer
- US08816079B2
Verknüpfte Notizen
Wird geladen…